Patents by Inventor Grant McNaughton-Smith

Grant McNaughton-Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150175585
    Abstract: A compound having the formula (I): for use in treating a disease; a composition comprising said fused quinonic compound of formula (I) and at least one pharmaceutically acceptable carrier; as well as a method of modulating a Janus Kinase-Signal Transduction and Activators of Transcription (JAK-STAT) pathway. The activation of a JAK and/or STAT pathways are associated with several disease states such as immunological and inflammatory diseases, hyperproliferative disorders including cancer, and myeloproliferative diseases.
    Type: Application
    Filed: July 23, 2013
    Publication date: June 25, 2015
    Applicant: CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED S.A.)
    Inventors: Grant McNaughton Smith, Ana Estévez Braun, Sandra Jiménez Alonso, Ángel Domingo Gutiérrez Ravelo, Leandro Fernández Pérez, Bonifacio Nicolás Díaz Chico
  • Publication number: 20100190746
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Application
    Filed: November 20, 2009
    Publication date: July 29, 2010
    Applicant: ICAGEN, INC.
    Inventors: Grant A. McNaughton-Smith, James B. Thomas, JR., George S. Amato
  • Publication number: 20080058319
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Application
    Filed: April 26, 2007
    Publication date: March 6, 2008
    Applicant: Icagen, Inc.
    Inventors: Grant McNaughton-Smith, George Amato, James Thomas
  • Patent number: 7205307
    Abstract: The present invention provides a genus of pyrimidine amides that are useful as openers of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: April 17, 2007
    Assignee: Icagen, Inc.
    Inventors: Grant A. McNaughton-Smith, George S. Amato, Paul C. Fritch
  • Publication number: 20070004784
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
    Type: Application
    Filed: September 7, 2006
    Publication date: January 4, 2007
    Applicant: Icagen, Inc.
    Inventors: Grant McNaughton-Smith, Aimee Reed, Robert Atkinson
  • Patent number: 7119112
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: October 10, 2006
    Assignee: ICAgen, Inc.
    Inventors: Grant A. McNaughton-Smith, Aimee D. Reed, Robert N. Atkinson
  • Publication number: 20060094721
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
    Type: Application
    Filed: August 14, 2003
    Publication date: May 4, 2006
    Applicant: Icagen, Inc.
    Inventors: Grant McNaughton-Smith, Aimee Reed, Robert Atkinson
  • Patent number: 6989398
    Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: January 24, 2006
    Assignee: ICAgen, Inc.
    Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
  • Publication number: 20050267032
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfone-containing prodrugs, and compositions and methods utilizing sulfone-containing prodrugs that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
    Type: Application
    Filed: May 23, 2005
    Publication date: December 1, 2005
    Applicant: Icagen, Inc.
    Inventors: Alan Fulp, Grant McNaughton-Smith, Aimee Reed, Xiadong Wang
  • Publication number: 20050059823
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Application
    Filed: September 10, 2004
    Publication date: March 17, 2005
    Applicant: Icagen, Inc.
    Inventors: Grant McNaughton-Smith, George Amato, James Thomas
  • Publication number: 20040198724
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
    Type: Application
    Filed: December 23, 2003
    Publication date: October 7, 2004
    Applicant: ICAgen, Inc.
    Inventors: Grant A. McNaughton-Smith, James B. Thomas, George S. Amato
  • Publication number: 20040157829
    Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
    Type: Application
    Filed: February 2, 2004
    Publication date: August 12, 2004
    Applicant: ICAgen, Inc.
    Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
  • Publication number: 20040106613
    Abstract: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
    Type: Application
    Filed: August 14, 2003
    Publication date: June 3, 2004
    Applicant: Icagen, Inc.
    Inventors: Grant A. McNaughton-Smith, Aimee D. Reed, Robert N. Atkinson
  • Patent number: 6737422
    Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: May 18, 2004
    Assignee: ICAgen, Inc.
    Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
  • Publication number: 20040029771
    Abstract: This invention relates to the use of compounds able to decrease potassium ion flow through intermediate conductance calcium activated potassium channels for treatment of diseases related to increased intraocular pressure modulated by intermediate conductance calcium activated potassium channels.
    Type: Application
    Filed: February 28, 2003
    Publication date: February 12, 2004
    Applicant: Icagen, Inc.
    Inventors: Gregory C. Rigdon, Jonathan W. Stocker, Grant A. McNaughton-Smith
  • Publication number: 20030181465
    Abstract: The present invention provides a genus of pyrimidine amides that are useful as openers of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.
    Type: Application
    Filed: November 27, 2002
    Publication date: September 25, 2003
    Applicant: Icagen, Inc.
    Inventors: Grant A. McNaughton-Smith, George S. Amato, Paul C. Fritch
  • Patent number: 6605725
    Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: August 12, 2003
    Assignee: ICAgen, Inc.
    Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
  • Patent number: 6495550
    Abstract: The present invention provides a genus of pyridine-substituted benzanilides that are useful as openers of potassium ion channels. The compounds of the invention are of use in both therapeutic and diagnostic methods.
    Type: Grant
    Filed: February 2, 2001
    Date of Patent: December 17, 2002
    Assignee: ICAgen, Inc.
    Inventors: Grant McNaughton-Smith, Paul Christopher Fritch, George Salvatore Amato
  • Publication number: 20020091122
    Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
    Type: Application
    Filed: December 6, 2001
    Publication date: July 11, 2002
    Applicant: Icagen, Inc.
    Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden
  • Publication number: 20020052393
    Abstract: Benzanilides are provided which are voltage-dependent potassium channel openers. Methods of using the benzanilides of the invention are also provided.
    Type: Application
    Filed: November 2, 2001
    Publication date: May 2, 2002
    Applicant: Icagen, Inc.
    Inventors: Grant A. McNaughton-Smith, Michael F. Gross, Alan D. Wickenden